JHS Svendgaard Laboratories Limited has informed the Exchange regarding Cessation of Mr. Mukul Pathak as Non- Executive Independent Director of the company w.e.f. July 01, 2025.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JHS Svendgaard Laboratories informed the stock exchanges about changes approved at its board meeting on July 1, 2025. The board re-appointed Mr. Nikhil Nanda as Managing Director for a fresh five-year term starting July 2, 2025, subject to shareholder approval. Mr. Nanda, a first-generation entrepreneur with over 30 years of FMCG experience, was already serving as MD and his prior term ended on July 1, 2025. Separately, Mr. Mukul Pathak ceased to be an Independent Director after completing his second consecutive term on the board. Consequently, the Nomination and Remuneration Committee has been reconstituted effective July 2, 2025.
This is a routine governance update with no material disruption. Continuity at the top is maintained with the MD's re-appointment, while the independent director's exit is due to the regulatory cap on consecutive terms, not any governance concern. Investors should watch for the shareholder approval outcome for the MD re-appointment at the upcoming AGM.